Changchun High & New Technology Industries (Group) Inc. (SHE: 000661) announced that its controlling subsidiary, GeneScience Pharmaceuticals Co., Ltd., has received the Acceptance Notice issued by China’s National Medical Products Administration (NMPA) for the domestic clinical trial application of GenSci161 Injection – a self‑developed novel fully human monoclonal IgG1 bispecific antibody intended for the treatment of recurrent pericarditis (RP), simultaneously targeting both IL‑1α and IL‑1β.
Regulatory Milestone
| Item | Detail |
|---|---|
| Agency | NMPA (China) |
| Application Type | Domestic drug registration clinical trial application |
| Acceptance No. | CXSL2601084 |
| Product | GenSci161 Injection |
| Indication | Recurrent pericarditis (RP) |
| Applicant | GeneScience Pharmaceuticals Co., Ltd. (Changchun High & New Technology Industries Group, SHE: 000661) |
| Review Conclusion | Application accepted for review |
| Next Steps | NMPA technical review toward clinical trial approval; timeline not disclosed |
Drug Profile & Mechanism of Action
- Molecule: GenSci161 Injection, a Class 1 therapeutic biologic independently developed by GeneScience Pharmaceuticals – a novel fully human monoclonal IgG1 bispecific antibody.
- Dual Target: Simultaneously targets the two IL‑1 subtypes driving RP – IL‑1α and IL‑1β – inhibiting IL‑1‑mediated inflammatory initiation and amplification, thereby reducing disease inflammatory activity and the risk of recurrence.
- Pathway Rationale: Recent research shows RP – particularly idiopathic RP – involves an autoinflammatory mechanism characterized by abnormal activation of innate immunity, in which the NLRP3 inflammasome and the key pro‑inflammatory cytokine interleukin‑1 (IL‑1) pathway play central roles in disease onset and recurrence.
- Molecular Cascade: Pericardial tissue injury induces IL‑1α release and promotes IL‑1β production; both cytokines act through the IL‑1 receptor to recruit inflammatory cells and amplify the pericardial inflammatory response – a dual‑cytokine loop GenSci161 is designed to interrupt at both nodes.
- Differentiation: Full human IgG1 bispecific format targeting both IL‑1 ligands distinguishes GenSci161 from single‑cytokine biologics in the IL‑1 blockade class.
Disease Landscape – Recurrent Pericarditis (RP)
- Definition: RP is a pericardial inflammatory disease recurring after remission of acute pericarditis.
- Recurrence Rate: Approximately 15%–30% of acute pericarditis patients experience recurrence.
- Patient Burden: Repeated episodes can significantly impair physical function, quality of life and work capacity, while increasing the medical burden.
- Unmet Need: Despite treatment with non‑steroidal anti‑inflammatory drugs (NSAIDs), colchicine and glucocorticoids, a subset of patients continues to suffer repeated relapses or develops glucocorticoid dependence – leaving substantial demand for targeted biologic therapy.
Clinical Development Status – Multi‑Indication Pipeline
| Indication | Regulatory Status |
|---|---|
| Recurrent Pericarditis (RP) | NMPA domestic clinical trial application accepted (this announcement) |
| Endometriosis (EM) | NMPA domestic clinical trial application approved |
| Moderate‑to‑severe Hidradenitis Suppurativa (HS) | NMPA domestic clinical trial application approved |
| Non‑infectious Uveitis (NIU) | NMPA domestic clinical trial application approved |
| Hidradenitis Suppurativa (HS) | FDA approval obtained for overseas‑manufactured product clinical trial application |
| Connective Tissue Disease‑associated Interstitial Lung Disease (CTD‑ILD) | NMPA domestic clinical trial application accepted |
Market Impact & Outlook
- Autoinflammation Platform Build‑Out: The RP acceptance extends GenSci161’s footprint across IL‑1‑driven autoinflammatory and immune‑mediated diseases, complementing already‑cleared programs in endometriosis, hidradenitis suppurativa and non‑infectious uveitis.
- Global Footprint: With FDA clearance for HS alongside multiple NMPA approvals, GeneScience is establishing a dual China‑US clinical development pathway for its bispecific antibody franchise.
- Strategic Fit: The company stated that smooth progress of the subsidiary’s clinical trial applications would help broaden its business structure, optimize its product portfolio, enrich strategic pipeline layout and enhance core competitiveness.
- RP Therapeutic Opportunity: As an indication marked by steroid dependence and relapse, RP represents a niche but high‑unmet‑need market where a dual IL‑1α/IL‑1β blocker could offer differentiated disease control versus existing anti‑inflammatory standards.
Forward‑Looking Statements
This brief contains forward‑looking statements regarding GenSci161 Injection‘s clinical development in recurrent pericarditis and its other pipeline indications, including NMPA and FDA review outcomes, trial timelines and commercial expectations. Actual results may differ materially due to risks including the uncertainties of drug review and approval, clinical trial outcomes and evolving competitive dynamics; the acceptance of the clinical trial application does not itself imply approval to market the product.-Fineline Info & Tech
